{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:18Z","timestamp":1792979898130,"version":"4.5.0"},"reference-count":12,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:00:00Z","timestamp":1715558400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Tenofovir-lamivudine-dolutegravir (TLD) is the preferred first-line antiretroviral therapy (ART) regimen. An additional 50-mg dose of dolutegravir (TLD+50) is required with rifampin-containing tuberculosis (TB) co-treatment. There are limited data on the effectiveness of TLD+50 in individuals with TB\/human immunodeficiency virus (HIV).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed a prospective, observational cohort study at 12 sites in Haiti, Kenya, Malawi, South Africa, Uganda, and Zimbabwe. Participants starting TLD and rifampin-containing TB treatment were eligible. The primary outcome was HIV-1 RNA \u22641000\u2005copies\/mL at end of TB treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We enrolled 91 participants with TB\/HIV: 75 (82%) ART-naive participants starting TLD after a median 15 days on TB treatment, 10 (11%) ART-naive participants starting TLD and TB treatment, 5 (5%) starting TB treatment after a median 3.3 years on TLD, and 1 (1%) starting TB treatment and TLD after changing from efavirenz-lamivudine-tenofovir. Median age was 37 years, 35% were female, the median CD4 count was 120\u2005cells\/mm3 (interquartile range, 50\u2013295), and 87% had HIV-1 RNA &amp;gt;1000\u2005copies\/mL. Among 89 surviving participants, 80 were followed to TB treatment completion, including 7 who had no HIV-1 RNA result due to missed visits. The primary virologic outcome was assessed in 73 participants, 69 of whom (95%; 95% confidence interval, 89%\u2013100%) had HIV-1 RNA \u22641000\u2005copies\/mL. No dolutegravir resistance mutations were detected among 4 participants with HIV-1 RNA &amp;gt;1000\u2005copies\/mL.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In programmatic settings, concurrent rifampin-containing TB treatment and TLD+50 was feasible, well tolerated, and achieved high viral suppression rates in a cohort of predominantly ART-naive people with TB\/HIV.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciae269","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T18:40:56Z","timestamp":1715625656000},"page":"137-143","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of Double-Dose Dolutegravir in People Receiving Rifampin-based Tuberculosis Treatment: An Observational, Cohort Study of People With HIV From 6 Countries"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6069-0857","authenticated-orcid":false,"given":"N Sarita","family":"Shah","sequence":"first","affiliation":[{"name":"Emory Rollins School of Public Health, Emory University , Atlanta, Georgia ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cissy","family":"Kityo","sequence":"additional","affiliation":[{"name":"Joint Clinical Research Centre , Kampala ,","place":["Uganda"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D","family":"Hughes","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T. H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlyn","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Center for Biostatistics in AIDS Research in the Department of Biostatistics, Harvard T. H. Chan School of Public Health , Boston, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole L","family":"Wallis","sequence":"additional","affiliation":[{"name":"Lancet Laboratories and BARC-SA , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina C","family":"Hosseinipour","sequence":"additional","affiliation":[{"name":"University of North Carolina at Chapel Hill, School of Medicine, Department of Medicine, Chapel Hill , North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Langat","sequence":"additional","affiliation":[{"name":"Department of Research, Walter Reed Project\u2013Kericho ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mulinda","family":"Nyirenda","sequence":"additional","affiliation":[{"name":"College of Medicine, Johns Hopkins Research Project , Blantyre ,","place":["Malawi"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Rassool","sequence":"additional","affiliation":[{"name":"Clinical HIV Research Unit, Wits Health Consortium, Health Science Research Office, Faculty of Health Sciences, University of the Witwatersrand , Johannesburg ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Dawson","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvetot","family":"Joseph","sequence":"additional","affiliation":[{"name":"GHESKIO Institute of Infectious Diseases and Reproductive Health , Port-au-Prince ,","place":["Haiti"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma","family":"Some","sequence":"additional","affiliation":[{"name":"Department of Medicine, Moi University Clinical Research Centre , Eldoret ,","place":["Kenya"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosie","family":"Mngqibisa","sequence":"additional","affiliation":[{"name":"Durban Clinical Research Site , Enhancing Care Foundation, Wentworth Hospital, Durban ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela Grace","family":"Mukwekwerere","sequence":"additional","affiliation":[{"name":"Milton Park Clinical Research Site, University of Zimbabwe , Harare ,","place":["Zimbabwe"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Woolley","sequence":"additional","affiliation":[{"name":"Social & Scientific Systems, Inc, A DLH Holdings Company , Bethesda, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Godfrey","sequence":"additional","affiliation":[{"name":"Bureau of Global Health Security and Diplomacy\/PEPFAR, US Department of State , Washington, DC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari C","family":"Manabe","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Pharmacology, and International Health, Johns Hopkins University School of Medicine and Bloomberg School of Public Health , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W","family":"Mellors","sequence":"additional","affiliation":[{"name":"University of Pittsburgh , Pittsburgh, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Flexner","sequence":"additional","affiliation":[{"name":"Departments of Medicine, Pharmacology, and International Health, Johns Hopkins University School of Medicine and Bloomberg School of Public Health , Baltimore, Maryland ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Cape Town , Cape Town ,","place":["South Africa"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ACTG A5381\/Hakim Study Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vuyokazi S","family":"Jezile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thando","family":"Mwelase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jude Jean","family":"Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphie Jean","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Siika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Kirui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penelope","family":"Madlala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petronella","family":"Casey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wadzanai","family":"Samaneka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeukai","family":"Musodza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Magengo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suri","family":"Moonsamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,5,13]]},"reference":[{"key":"2025020710473285100_ciae269-B1","article-title":"Update of recommendations on first- and second-line antiretroviral regimens","author":"World Health Organization.","year":"2019"},{"key":"2025020710473285100_ciae269-B2","volume-title":"Update on the transition to dolutegravir-based antiretroviral therapy: report of a WHO meeting, 29\u201330 March 2022","author":"World Health Organization","year":"2022"},{"key":"2025020710473285100_ciae269-B3","doi-asserted-by":"crossref","first-page":"e284","DOI":"10.1016\/S2352-3018(23)00047-4","article-title":"Implementation and outcomes of dolutegravir-based first-line antiretroviral therapy for people with HIV in South Africa: a retrospective cohort study","volume":"10","author":"Dorward","year":"2023","journal-title":"Lancet HIV"},{"key":"2025020710473285100_ciae269-B4","volume-title":"WHO consolidated guidelines on tuberculosis. Module 4: treatment\u2014drug-susceptible tuberculosis treatment","author":"World Health Organization","year":"2022"},{"key":"2025020710473285100_ciae269-B5","doi-asserted-by":"crossref","first-page":"e463","DOI":"10.1016\/S2352-3018(19)30154-7","article-title":"Management of active tuberculosis in adults with HIV","volume":"6","author":"Meintjes","year":"2019","journal-title":"Lancet HIV"},{"key":"2025020710473285100_ciae269-B6","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2019.04.009","article-title":"Pharmacokinetics of dolutegravir 100\u2005mg once daily with rifampicin","volume":"54","author":"Wang","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2025020710473285100_ciae269-B7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/cid\/ciz256","article-title":"Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial","volume":"70","author":"Dooley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025020710473285100_ciae269-B8","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3018(23)00081-4","article-title":"Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial","volume":"10","author":"Griesel","year":"2023","journal-title":"Lancet HIV"},{"key":"2025020710473285100_ciae269-B9","author":"Division of AIDS (DAIDS). US Department of Health and Human Services"},{"key":"2025020710473285100_ciae269-B10","doi-asserted-by":"crossref","first-page":"e25961","DOI":"10.1002\/jia2.25961","article-title":"Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa","volume":"25","author":"Romo","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"2025020710473285100_ciae269-B11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/QAI.0000000000002126","article-title":"Clinical and virological outcomes of TB\/HIV coinfected patients treated with dolutegravir-based HIV antiretroviral regimens: programmatic experience from Botswana","volume":"82","author":"Modongo","year":"2019","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025020710473285100_ciae269-B12","doi-asserted-by":"crossref","first-page":"e422","DOI":"10.1016\/S2352-3018(23)00115-7","article-title":"Dolutegravir once daily with rifampicin for HIV and tuberculosis","volume":"10","author":"Naidoo","year":"2023","journal-title":"Lancet HIV"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciae269\/58614289\/ciae269.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/137\/58614289\/ciae269.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/80\/1\/137\/58614289\/ciae269.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T10:48:01Z","timestamp":1738925281000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/80\/1\/137\/7671065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,13]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,5,13]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciae269","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1,15]]},"published":{"date-parts":[[2024,5,13]]}}}